Mounjaro Mounjaro contains tirzepatide, a dual GLP-1 and glucose-independent polypeptide (GIP) agonist that is thought to enhance its effects on weight loss and blood sugar control
Sales hit $2.35 billion in 2025, up 59% year over year, but analysts expect growth to moderate sharply in 2026 to around 16%
Buyer Takeaway 21: Wegovy's FDA-reviewed prescribing information discloses that in the SELECT cardiovascular outcomes trial, hip and pelvis fractures occurred more often in female patients on Wegovy than placebo (1% vs
Hair loss, which often occurs due to rapid weight loss rather than the medication itself, still deserves attention because it shows how quickly your body is changing
Randomized Controlled Trial of Oral Glutathione Supplementation.
These inherent defects greatly limit the repeatability and clinical popularization of buccal semaglutide delivery, necessitating targeted formulation modification and delivery system optimization to break through barrier restrictions